ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ...

BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with ...

Presentation of encouraging preclinical results for CER-1236 in ovarian cancer, indicating potential effectiveness of the treatment. No observed toxicity in animal models after treatment, highlighting ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...

In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.

Eterna Therapeutics announced promising preclinical results for its lead cell therapy, ERNA-101, aimed at treating ovarian cancer by activating the immune system. In a study conducted at MD Anderson, ...

Ovarian cancer is one of the most common forms of cancer, a type that usually remains undiagnosed for a while in many ...